169 related articles for article (PubMed ID: 12621790)
1. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life.
Borenstein J; Yu HT; Wade S; Chiou CF; Rapkin A
J Reprod Med; 2003 Feb; 48(2):79-85. PubMed ID: 12621790
[TBL] [Abstract][Full Text] [Related]
2. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
Brown C; Ling F; Wan J
J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
[TBL] [Abstract][Full Text] [Related]
3. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
4. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
[TBL] [Abstract][Full Text] [Related]
5. Quality of life issues. Potential role for an oral contraceptive containing ethinyl estradiol and drospirenone.
Dickerson V
J Reprod Med; 2002 Nov; 47(11 Suppl):985-93. PubMed ID: 12497673
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
7. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
8. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
Endrikat J; Sandri M; Gerlinger C; Rübig A; Schmidt W; Fortier M
Eur J Contracept Reprod Health Care; 2007 Sep; 12(3):220-8. PubMed ID: 17763260
[TBL] [Abstract][Full Text] [Related]
9. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
10. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
[TBL] [Abstract][Full Text] [Related]
11. YAZ and the novel progestin drospirenone.
Mishell DR
J Reprod Med; 2008 Sep; 53(9 Suppl):721-8. PubMed ID: 18980044
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Yasmin in premenstrual symptoms.
Taneepanichskul S; Jaisamrarn U; Phupong V
Arch Gynecol Obstet; 2007 Jun; 275(6):433-8. PubMed ID: 17111156
[TBL] [Abstract][Full Text] [Related]
13. Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada.
Endrikat JS; Milchev NP; Kapamadzija A; Georgievska J; Gerlinger C; Schmidt W; Feroze S
Contraception; 2009 Jun; 79(6):428-32. PubMed ID: 19442777
[TBL] [Abstract][Full Text] [Related]
14. Use of an oral contraceptive containing drospirenone in an extended regimen.
Sillem M; Schneidereit R; Heithecker R; Mueck AO
Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328
[TBL] [Abstract][Full Text] [Related]
15. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of drospirenone-ethinylestradiol on contraception in healthy Chinese women: a multicenter randomized controlled trial].
Fan GS; Bian ML; Cheng LN; Cao XM; Huang ZR; Han ZY; Jing XP; Li J; Wu SY; Xiong CL; Xiong ZA; Yue TF
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):38-44. PubMed ID: 19563061
[TBL] [Abstract][Full Text] [Related]
17. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
Freeman EW
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
[TBL] [Abstract][Full Text] [Related]
19. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
Coffee AL; Kuehl TJ; Sulak PJ
Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
[TBL] [Abstract][Full Text] [Related]
20. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
Boschitsch E; Skarabis H; Wuttke W; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
